Madden Securities’s Jazz Pharmaceuticals JAZZ Stock Holding History

Madden Securities’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-60	Closed	-$9.56K	–	218
2022 Q4	$9.56K	Buy	+60	New	+$8.79K	0.01%	316

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Madden Securities's JAZZ Position: Q1 2023 in Review

Madden Securities sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 60 shares — an estimated $9.56K sold.

Madden Securities first reported a position in JAZZ in Q4 2022 and held it in 1 quarter. The position peaked at $9.56K in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Madden Securities reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Madden Securities sold 60 Jazz Pharmaceuticals shares in Q1 2023, an estimated $9.56K.
Madden Securities first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Madden Securities's Jazz Pharmaceuticals position peaked at $9.56K in Q4 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Madden Securities's 13F filing for Q1 2023, filed 21 Apr 2023.